

02-01-07

1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jayanta Roy-Chowdhury

Serial No.: 08/808,629

Filed: February 28, 1997

Title: NOVEL PROCESSES IMPLEMENTING
SELECTIVE IMMUNE DOWN
REGULATION (SIDR)

Group Art Unit: 1644

Examiner: Ronald B. Schwadron

527 Madison Avenue, 9th Floor
New York, New York 10022
January 31, 2007

FILED BY EXPRESS MAIL

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sirs:

In accordance with 37 C.F.R. §§1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicants submit attached Form PTO-SB/08A for consideration and request the references cited therein be made of record by the U.S. Patent and Trademark Office (the "USPTO") in the above-captioned application.

EXPRESS MAIL CERTIFICATE

"Express Mail" Label No.: **EV655205190US**

Deposit Date: **January 31, 2007**

I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents, P.O. Box 1450, Alexandria, Virginia, 22313-1450.

Natalie Bogdanos
Natalie Bogdanos
Reg. No. 51,480

1/31/07
Date

TECH CENTER 1600/2900

FEB 07 2007

RECEIVED

In accordance with 37 C.F.R. § 1.98(a)(2)(ii), copies of cited U.S. patents and/or U.S. patent application publications are not being provided.

Applicants point out the following six (6) applications that are co-pending with the instant Application at the USPTO and listed in the attached Form PTO/SB/08A:

US 2003-0170258 A1, published 09-11-2003 (Roy-Chowdhury, et al.);

US 2004-0022768 A1, published 02-05-2004 (Roy-Chowdhury, et al.);

US 2004-0023909 A1, published 02-05-2004 (Roy-Chowdhury, et al.);

Co-pending U.S. Appl. No. 09/356,294, filed July 16, 1999 (Roy-Chowdhury, et al. (unpublished);

Co-pending U.S. Appl. No 09/171,909, filed May 9, 2001 (Roy-Chowdhury, et al. (unpublished); and

Co-pending U.S. Appl. No. 11/378,158, filed March 16, 2006 (unpublished).

Applicants respectfully point out that the submission of the listed references in this Supplemental Information Disclosure Statements is not an admission that they are prior art or that they are material to patentability of any claims of the application. Also, the submission of this Supplemental Information Disclosure Statement is not an indication that a search has been made by Applicants.

For the convenience of the Examiner in considering the cited references, a copy of each of the cited references is enclosed with this communication. In considering the cited references, it may be noted by the Examiner that certain of the references may contain markings, underlinings, and/or other notations. These markings, underlinings, and/or other notations are not to be construed as drawing the Examiner's attention either to selected parts or away from other parts of the cited references. Any such markings were either present on the copies of the cited references obtained by the associated individuals, or were made thereon during the study of the references by the individuals.

Jayanta Roy-Chowdhury, et al.

Serial No. 08/808,629

Filed: February 28, 1997


Page 3 (Supplemental Information Disclosure Statement) – January 31, 2007)

Consideration of the foregoing plus the prompt return of the enclosed Form SB/08A with the Examiner's initials in the left column in accordance with MPEP §609 are respectfully requested.

In accordance with 37 C.F.R. §1.97(b), this Supplemental Information Disclosure Statement is believed to be submitted prior to issuance of a first office action. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, if any other fee or fees are due, the USPTO is hereby authorized to charge the amount of any such fee to Deposit Account No. 05-1135, or to credit any overpayment thereto.

If helpful to processing this reply, the undersigned may be contacted by telephone at (212) 583-0100 during business hours.

Respectfully submitted,



Natalie Bogdanos
Registration No. 51,480
Attorney for Applicants

ENZO THERAPEUTICS, INC.

c/o Enzo Biochem, Inc.

527 Madison Avenue (9th Fl.)

New York, New York 10022

Telephone: (212) 583-0100; Fax: (212) 583-0150

al/USProsecution/Enz-55.SuppIDS.013107

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	08/808,629
Filing Date	February 28, 1997
First Named Inventor	Jayanta Roy-Chowdhury
Art Unit	1644
Examiner Name	Ronald B. Schwadron
Attorney Docket Number	Enz-55

Sheet 1

of

4

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US- 4,950,469	08-21-1990	Katz	
	2	US- 5,849,285	12-15-1998	Selawry	
	3	US- 5,788,968	08-04-1998	Weiner, et al.	
	4	US- 5,861,290	1/1999	Goldsmith, et al.	
	5	US- 6,358,509	3/2002	Ramanathan, et al.	
	6	US- 5,935,575	8/1999	Lenardo, et al.	
	7	US- 5,872,154	2/1999	Wilson, et al.	
	8	US- 2003-0170258-A1	09-11-2003	Roy-Chowdhury, et al.	
	9	US- 2004-0022768-A1	02-05-2004	Roy-Chowdhury, et al.	
	10	US- 2004-0023909-A1	02-05-2004	Roy-Chowdhury, et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	11	WO 96/39176	12-12-1996	Chen, et al.		
	12	WO 94/27622	12-08-1994	Beschorner		
	13	WO 98/37917	09-03-1998	Roy-Chowdhury, et al.		
	14	EP 0 914 163	05-12-1999	Roy-Chowdhury, et al.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	08/808,629
Filing Date	February 28, 1997
First Named Inventor	Jayanta Roy-Chowdhury
Art Unit	1644
Examiner Name	Ronald B. Schwadron
Attorney Docket Number	Enz-55

Sheet

2

of

4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	15	Abandoned U.S. Appl. No. 08/808,629 filed February 28, 1997. (Roy-Chowdhury, et al.) (unpublished)	
	16	Co-pending U.S. Appl. No. 09/356,294 filed July 16, 1999. (Roy-Chowdhury, et al.) (unpublished)	
	17	Co-pending U.S. Appl. No. 09/171,909 filed on May 9, 2001. (Roy-Chowdhury, et al.) (unpublished)	
	18	Co-pending U.S. Appl. No. 11/378,158 filed on March 16, 2006. (unpublished)	
	19	European Search Report dated June 29, 2001 for European Application No. EP 98912887.1 filed February 26, 1998.	
	20	European Search Report dated August 22, 2001 for European Application No. EP 00115423.6 filed February 26, 1998.	
	21	February 8, 2005 Translation of Substantive Examination Report (redacted) cited two (2) references for Israeli Patent Appl. No. 126,714.	
	22	International Search Report dated June 23, 1998 for International Application No. PCT/US98/03606 filed February 26, 1998.	
	23	International Search Report dated September 15, 2004 for International Application No. PCT/US03/33178 filed October 17, 2003.	
	24	Baggi, et al., "Oral Administration of an Immunodominant T-cell Epitope Downregulates Th1/Th2..." The Journal of Clinical Investigation, Vol. 104, No.9, pg.1287-1295, Nov 1999.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3

of

4

Complete if Known

Application Number	08/808,629
Filing Date	February 28, 1997
First Named Inventor	Jayanta Roy-Chowdhury
Art Unit	1644
Examiner Name	Ronald B. Schwadron
Attorney Docket Number	Enz-55

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	25	van der Lubben, Inez, M. et al., "Chitosan and Its Derivatives in Mucosal Drug and Vaccine Delivery" European Journal of Pharmaceutical Sciences, Vol. 14, pg. 201-207, 2001.	
	26	Ninomiya, et al., "Intranasal Administration of a Synthetic Peptide Vaccine Encapsulated in Liposome Together with an Anti-CD40..." Vaccine, Vol. 20, pg. 3123-3129, 2002.	
	27	Guzzetta et al., "Induction of Kidney Transplantation Tolerance Across Major Histocompatibility Complex Barriers..." Transplantation, 51(4):862:866 (1991).	
	28	Madsen et al., "Immunological Unresponsiveness Induced by Recipient Cells Transfected with Donor MHC Genes" Nature, 332:161-164 (1988).	
	29	Moller et al., "Cellular Mechanisms Underlying Differential Rejection of Sequential Heart and Lung..." Transplantation, 55(3):650-655 (1993).	
	30	Pearson et al., "Induction of Transplantation Tolerance in Adults Using Donor Antigen and Anti-CD4 Monoclonal Antibody" Transplantation, 54(3):475-483 (1992).	
	31	Rosengard et al., "Induction of Specific Tolerance to Class I-Disparate Renal Allografts in Minature..." Transplantation, 54(3):490-497 (1992).	
	32	Sharabi et al., "Specific Tolerance Induction Across a Xenogeneic Barrier: Production of Mixed Rat/Mouse..." The Journal of Exp Med, 172:195-202 (1990).	
	33	Smith et al., "New Approaches to Transplantation Tolerance" Transplantation Proceedings, 23(4):2157-2161 (1991).	
	34	Sykes et al., "Bone Marrow Transplantation as a Means of Inducing Tolerance Seminars in Immunology, 2:401-417 (1990).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	08/808,629
Filing Date	February 28, 1997
First Named Inventor	Jayanta Roy-Chowdhury
Art Unit	1644
Examiner Name	Ronald B. Schwadron
Attorney Docket Number	Enz-55

Sheet 4

of

4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	35	Thomas et al., "Beneficial Effect of Cyclosporine in Posttransplantation Induction of..." Transplantation Proceedings, XX(1):134-136 (Suppl. 1 1988).	
	36	McMenamin et al., "Regulation of IgE Responses to Inhaled Antigen in Mice by Antigen Specific yo T Cells" Science, 265:1869-1871 (1994).	
	37	Pearson et al., "Effect of Anti-CD4 Monoclonal Antibody Dosage When Combined with Donor Antigen..." Transplantation Proceedings, 23(1):565-566 (1991).	
	38	Graham et al., Methods in Molecular Biology, 109-128 (The Human Press 1991).	
	39	Weiner, H.L. and Mayer, L.F. (Eds.), "Oral Tolerance: Mechanisms and Applications", Annals of the New York Academy of Sciences, Vol. 778 (1996).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.